Evidence map›Paper›PMID 31452838›Full record

ArticleOncotarget2019

Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy.

Cornelia Schroeder, Elham Navid-Hill, Jan Meiners, Claudia Hube-Magg, Martina Kluth, Georgia Makrypidi-Fraune, Ronald Simon, Franziska Büscheck, Andreas M Luebke, Cosima Goebel and 13 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. The Diseased Mitoribosome.FEBS letters · 2021
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 1 country.

Cornelia Schroeder *Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Elham Navid-Hill *Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jan MeinersGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Claudia Hube-MaggInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Martina KluthInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Georgia Makrypidi-FrauneInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ronald SimonInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Franziska BüscheckInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andreas M LuebkeInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Cosima GoebelInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Dagmar S LangInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sören WeidemannInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Emily NeubauerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andrea HinschInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Frank JacobsenInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Patrick LebokInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Uwe MichlMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Dirk PehrkeMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Hartwig HulandMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Markus GraefenMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thorsten SchlommMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Guido SauterInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Doris HöflmayerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
University Medical Center Hamburg-Eppendorf · DEUniversität Hamburg · DEMartini-Klinik · DECharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ELAC2 is a ubiquitously expressed enzyme potentially involved in tRNA processing and cell signaling pathways. Mutations of the ELAC2 gene have been found to confer increased prostate cancer susceptibility in families. ELAC2 protein expression was analyzed by immunohistochemistry in 9,262 patients and Kaplan-Meier curves of PSA recurrence-free survival were calculated in 8,513 patients treated with radical prostatectomy. Nuclear ELAC2 staining was observed in 60.8% of prostate cancers. It was weak in 26.3%, moderate in 26.6% and strong in 7.9%. Strong nuclear ELAC2 expression was associated with advanced tumor stage, nodal metastasis, higher Gleason grade, presence of

Indexed as

ELAC2HPC2prognosisprostate cancertissue microarray

Identifiers

PMID31452838
PMCPMC6697635
OpenAlexW2991030163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.